Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study

BACKGROUND: The raw costs of mitomycin C (MMC) and oxaliplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) differ substantially. We sought to compare the morbidity and toxicity profiles associated with the use of oxaliplatin and MMC in patients undergoing cytoreductive surgery (CRS) and HI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Can J Surg
Main Authors: Benzaquen, Ella, Wang, Yifan, Wiseman, Stephanie, Rosenfeld, Velka, Sideris, Lucas, Dubé, Pierre, Pelletier, Jean-Sebastien, Vanounou, Tsafrir
Formato: Artigo
Idioma:Inglês
Publicado em: Joule Inc. 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8064255/
https://ncbi.nlm.nih.gov/pubmed/33651573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/cjs.001619
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados